150 related articles for article (PubMed ID: 36372398)
1. Comparing Characteristics of Pelvic High-grade Serous Carcinomas with and without Breast Cancer Gene Variants on MR Imaging.
Saida T; Shikama A; Mori K; Ishiguro T; Minaguchi T; Satoh T; Nakajima T
Magn Reson Med Sci; 2024 Jan; 23(1):18-26. PubMed ID: 36372398
[TBL] [Abstract][Full Text] [Related]
2. Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor.
D'Angelo E; Espinosa I; Felicioni L; Buttitta F; Prat J
Hum Pathol; 2023 Nov; 141():15-21. PubMed ID: 37673346
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance imaging findings of extrauterine high-grade serous carcinoma based on new pathologic criteria for primary site assignment.
Kawaguchi M; Kato H; Hatano Y; Tomita H; Hara A; Miyazaki T; Matsuo M
Acta Radiol; 2021 May; 62(5):687-694. PubMed ID: 32576024
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome.
Mitamura T; Sekine M; Arai M; Shibata Y; Kato M; Yokoyama S; Yamashita H; Watari H; Yabe I; Nomura H; Enomoto T; Nakamura S;
Jpn J Clin Oncol; 2020 Dec; 50(12):1380-1385. PubMed ID: 32676635
[TBL] [Abstract][Full Text] [Related]
5. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer.
Chay WY; McCluggage WG; Lee CH; Köbel M; Irving J; Millar J; Gilks CB; Tinker AV
Int J Gynecol Cancer; 2016 Mar; 26(3):431-6. PubMed ID: 26807643
[TBL] [Abstract][Full Text] [Related]
7. Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma.
Howitt BE; Hanamornroongruang S; Lin DI; Conner JE; Schulte S; Horowitz N; Crum CP; Meserve EE
Am J Surg Pathol; 2015 Mar; 39(3):287-93. PubMed ID: 25581732
[TBL] [Abstract][Full Text] [Related]
8. Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin.
Morency E; Leitao MM; Soslow RA
Int J Gynecol Pathol; 2016 May; 35(3):222-9. PubMed ID: 26630225
[TBL] [Abstract][Full Text] [Related]
9. Serous carcinoma of the ovary and peritoneum with metastases to the breast and axillary lymph nodes: a potential pitfall.
Recine MA; Deavers MT; Middleton LP; Silva EG; Malpica A
Am J Surg Pathol; 2004 Dec; 28(12):1646-51. PubMed ID: 15577686
[TBL] [Abstract][Full Text] [Related]
10. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma.
Chui MH; Momeni Boroujeni A; Mandelker D; Ladanyi M; Soslow RA
Mod Pathol; 2021 Feb; 34(2):490-501. PubMed ID: 32801341
[TBL] [Abstract][Full Text] [Related]
11. Carcinosarcoma of the ovary: MR and clinical findings compared with high-grade serous carcinoma.
Saida T; Mori K; Tanaka YO; Sakai M; Amano T; Kikuchi S; Masuoka S; Yoshida M; Masumoto T; Satoh T; Minami M
Jpn J Radiol; 2021 Apr; 39(4):357-366. PubMed ID: 33216290
[TBL] [Abstract][Full Text] [Related]
12. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
Hyman DM; Zhou Q; Iasonos A; Grisham RN; Arnold AG; Phillips MF; Bhatia J; Levine DA; Aghajanian C; Offit K; Barakat RR; Spriggs DR; Kauff ND
Cancer; 2012 Aug; 118(15):3703-9. PubMed ID: 22139894
[TBL] [Abstract][Full Text] [Related]
13. Association Between Germline
Luo Y; Pan R; Rao H; Chen X; Yang H
Int J Gen Med; 2024; 17():75-84. PubMed ID: 38226182
[TBL] [Abstract][Full Text] [Related]
14. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
Škapa P; Dundr P
Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446
[TBL] [Abstract][Full Text] [Related]
15. Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency.
Reyes MC; Arnold AG; Kauff ND; Levine DA; Soslow RA
Mod Pathol; 2014 Oct; 27(10):1405-11. PubMed ID: 24577588
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
McAlpine JN; Porter H; Köbel M; Nelson BH; Prentice LM; Kalloger SE; Senz J; Milne K; Ding J; Shah SP; Huntsman DG; Gilks CB
Mod Pathol; 2012 May; 25(5):740-50. PubMed ID: 22282309
[TBL] [Abstract][Full Text] [Related]
18. Association of BRCA Mutation Types, Imaging Features, and Pathologic Findings in Patients With Breast Cancer With BRCA1 and BRCA2 Mutations.
Ha SM; Chae EY; Cha JH; Kim HH; Shin HJ; Choi WJ
AJR Am J Roentgenol; 2017 Oct; 209(4):920-928. PubMed ID: 28796549
[TBL] [Abstract][Full Text] [Related]
19. Three primary malignancies related to BRCA mutation successively occurring in a BRCA1 185delAG mutation carrier.
Piura B; Rabinovich A; Yanai-Inbar I
Eur J Obstet Gynecol Reprod Biol; 2001 Aug; 97(2):241-4. PubMed ID: 11451557
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study.
Lertkhachonsuk AA; Suprasert P; Manchana T; Kittisiam T; Kantathavorn N; Chansoon T; Khunamornpong S; Pohthipornthawat N; Tangjitgamol S; Luasiripanthu T; Teerapakpinyo C; Shuangshot S; Iemwimangsa N; Chantratita W
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2381-2388. PubMed ID: 32856869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
